Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AEON Stock Forecast 2025-2026
$0.55
Current Price
$5.75M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AEON Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AEON Price Momentum
+10.0%
1 Week Change
+25.0%
1 Month Change
-99.5%
1 Year Change
-98.6%
Year-to-Date Change
-99.8%
From 52W High of $269.28
+46.4%
From 52W Low of $0.38
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching AEON Biopharma (AEON) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AEON and similar high-potential opportunities.
Latest AEON Stock Price Targets & Analyst Predictions
AEON has shown a year-to-date change of -98.6% and a 1-year change of -99.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AEON. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AEON Analyst Ratings
1
Buy
0
Hold
0
Sell
AEON Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.55
Latest AEON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AEON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 1, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $5.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $5.00 |
| Jul 10, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
| May 30, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $6.00 |
| May 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $6.00 |
| May 6, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Apr 17, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Aug 18, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $18.00 |
Aeon Biopharma Inc. (AEON) Competitors
The following stocks are similar to AEON Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aeon Biopharma Inc. (AEON) Financial Data
Aeon Biopharma Inc. has a market capitalization of $5.75M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -147.0%.
Valuation Metrics
Market Cap
$5.75M
Enterprise Value
$9.91M
P/E Ratio
0.0x
PEG Ratio
-0.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+168.3%
Current Ratio
1.4x
Debt/Equity
-1.3x
ROE
-147.0%
ROA
-158.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Aeon Biopharma Inc. (AEON) Business Model
About Aeon Biopharma Inc.
What They Do
Develops therapeutic treatments for medical conditions.
Business Model
The company focuses on research and development of innovative biopharmaceutical therapies, particularly in neurology and chronic disorders. It generates revenue through the commercialization of these novel therapies, potentially transforming treatment standards and improving patient outcomes.
Additional Information
Aeon Biopharma operates within the biopharmaceutical sector, engaging with healthcare providers and regulatory bodies while contributing to advancements in medical solutions. The company's commitment to pioneering treatments positions it to address unmet medical needs and capitalize on the growing demand for effective healthcare interventions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Robert Bancroft
Country
United States
IPO Year
2023
Website
www.aeonbiopharma.comAeon Biopharma Inc. (AEON) Latest News & Analysis
Latest News
Quick Summary
AEON Biopharma (NYSE: AEON) will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on May 21, 2025, at 7:00 a.m. PT / 10:00 a.m. ET.
Why It Matters
AEON Biopharma's CEO presentation could influence investor sentiment, highlighting potential developments in their botulinum toxin therapy and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
8 days ago
Quick Summary
The company is preparing for a potential FDA Biosimilar Biological Product Development Type 2a meeting, scheduled for the second half of 2025.
Why It Matters
The planned FDA meeting for a biosimilar product indicates potential future revenue and market entry, affecting company valuations and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AEON Biopharma, Inc. (NYSE: AEON) has received acceptance from NYSE American for its plan to regain compliance with listing standards related to market capitalization and stockholders' equity.
Why It Matters
AEON Biopharma's compliance with NYSE listing standards signals financial stability, potentially boosting investor confidence and stock performance as it develops key therapeutic products.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Former CEO Marc Forth will continue to serve on the Company's Board of Directors.
Why It Matters
Marc Forth's continued involvement on the Board may provide stability and continuity, influencing investor confidence and strategic direction amid leadership changes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
1 month ago
Quick Summary
AEON Biopharma announced the appointment of Rob Bancroft as CEO and the approval of inducement awards by its Compensation Committee. The company focuses on a botulinum toxin complex for therapeutic use.
Why It Matters
The appointment of a new CEO and the granting of inducement awards can signal strategic shifts and potential growth, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Announces CEO Transition
1 month ago
Quick Summary
Marc Forth is stepping down as President and CEO of AEON Biopharma effective April 4, 2025, to pursue another opportunity; Jost Fischer will serve as interim CEO.
Why It Matters
Leadership changes can create uncertainty about a company's strategic direction, potentially affecting investor confidence and stock performance in the short term.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AEON Stock
What is Aeon Biopharma Inc.'s (AEON) stock forecast for 2025?
Analyst forecasts for Aeon Biopharma Inc. (AEON) are not currently available. The stock is trading at $0.55.
Is AEON stock a good investment in 2025?
According to current analyst ratings, AEON has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AEON stock?
Price predictions from Wall Street analysts for AEON are not currently available. The stock is trading at $0.55.
What is Aeon Biopharma Inc.'s business model?
The company focuses on research and development of innovative biopharmaceutical therapies, particularly in neurology and chronic disorders. It generates revenue through the commercialization of these novel therapies, potentially transforming treatment standards and improving patient outcomes.
What is the highest forecasted price for AEON Aeon Biopharma Inc.?
Price targets from Wall Street analysts for AEON are not currently available. The stock is trading at $0.55.
What is the lowest forecasted price for AEON Aeon Biopharma Inc.?
Price targets from Wall Street analysts for AEON are not currently available. The stock is trading at $0.55.
What is the overall AEON consensus from analysts for Aeon Biopharma Inc.?
The overall analyst consensus for AEON is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are AEON stock price projections?
Stock price projections, including those for Aeon Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:02 AM UTC